Gilead Sciences, Inc.
Close on Nov 2, 2026Market cap $211.20BP/E –Yield 1.86%
Gilead Sciences Total HCV Franchise by Quarter
Total HCV Franchise (legacy sub-franchise breakout) — Worldwide YoY growth (%) (%)
Gilead Sciences Total HCV Franchise: 12.0% in Q4 2022, up 19.0 pts from a year earlier. No newer figure appears in the documents we track.
Where the Q4 2022 figure comes from
“|| HCV | 439 | 393 | 12% | 1,810 | 1,881 | (4)%”
Source: Form 8-K (exhibit991earningspressrel.htm, filed 2023-02-02) ↗
Reported in Form 8-K Total Revenue Summary.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Total HCV Franchise (legacy sub-franchise breakout) — Worldwide YoY growth (%) (%) | Year on year | Source |
|---|---|---|---|---|
| Q4 2022 | Dec 31, 2022 | 12.0% | +19.0 pts | Form 8-K (exhibit991earningspressrel.htm, filed 2023-02-02) ↗ |
| Q3 2022 | Sep 30, 2022 | 22.0% | +30.0 pts | Form 8-K (exhibit991earningspressrel.htm, filed 2022-10-27) ↗ |
| Q2 2022 | Jun 30, 2022 | -18.0% | -41.0 pts | Form 8-K (exhibit991earningspressrel.htm, filed 2022-08-02) ↗ |
| Q1 2022 | Mar 31, 2022 | -22.0% | +8.0 pts | Form 8-K (exhibit991earningspressrel.htm, filed 2022-04-28) ↗ |
| Q4 2021 | Dec 31, 2021 | -7.0% | – | Form 8-K (exhibit991earningspressrel.htm, filed 2022-02-01) ↗ |
| Q3 2021 | Sep 30, 2021 | -8.0% | – | Form 8-K (exhibit991earningspressrel.htm, filed 2021-10-28) ↗ |
| Q2 2021 | Jun 30, 2021 | 23.0% | – | Form 8-K (exhibit991earningspressrel.htm, filed 2021-07-29) ↗ |
| Q1 2021 | Mar 31, 2021 | -30.0% | – | Form 8-K (exhibit991earningspressrel.htm, filed 2021-04-29) ↗ |
Cite this data
StockData. (2026). Gilead Sciences Total HCV Franchise (%), quarterly Q1 2021–Q4 2022 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/liver-hcv-total-yoy
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.